CGP43182 is an effective inhibitor of group IIA secretory phospholipase A2 (Group IIA sPLA2) activity in vitro, which can be used to prevent the synergistic effect of pro-inflammatory genes stimulated by cytokines mediated by NFkappaB.
CGP43487 is an N-methyl-D-aspartic acid (NMDA) receptor antagonist. CGP43487, a competitive NMDA receptor antagonist, significantly increased the convulsive threshold.